조현병 및 조현정동장애 환자에서 항정신병약물에 의한 체중증가에 미치는 메트포르민의 영향: 체계적 문헌고찰 및 메타분석

키워드

참고문헌 (42)

1. American Psychiatric Association, "DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5™" (2013), American Psychiatric Publishing, Inc
2. Crismon M. L, "Pharmacotherapy: a pathophysiologic approach", pp.1022~1028 (2013), McGraw-Hill Education
3. "BIT Druginfo"[URL]
4. Hasan A, "World Federation of Societies of Biological Psychiatry(WFSBP) guidelines for the biological treatment of schizophrenia. Part 3: Update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation 2015", Send to World J Biol Psychiatry, 16, pp.142~170 (2015)
5. Lieberman JA, "Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353(12), pp.1209~1223 (2005)[DOI]
6. McEvoy JP, "CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment", Am J Psychiatry, 163(4), pp.600~610 (2006)[DOI]
7. Baptista T, "Body weight gain induced by antipsychotic drugs: mechanisms and management", Acta Psychiatr Scand, 100(1), pp.3~16 (1999)[DOI]
8. Hasnain M, "Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions", CNS Drugs, 24(3), pp.193~206 (2010)[DOI]
9. Pringsheim T, "Physical Health and Drug Safety in Individuals with Schizophrenia", Can J Psychiatry, 62(9), pp.673~683 (2017)[DOI]
10. Management of schizophrenia. SIGN Publication 131, "Scottish Intercollegiate Guidelines Network", SIGN, ~ (2013)
11. Chamberlain JJ, "Pharmacologic therapy for type 2 diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes", Ann Intern Med, 166(8), pp.572~578 (2017)[DOI]
12. Professional Practice Committee, "Standards of Medical Care in Diabetes-2018", Diabetes Care, 41(Suppl 1), pp.S3~ (2018)[DOI]
13. Klip A, "Cellular mechanism of action of metformin", Diabetes Care, 13(6), pp.696~704 (1990)[DOI]
14. Schultes B, "Modulation of hunger by plasma glucose and metformin", J Clin Endocrinol Metab, 88(3), pp.1133~1141 (2003)[DOI]
15. Seifarth C, "Effectiveness of metformin on weight loss in non-diabetic individuals with obesity", Exp Clin Endocri- nol Diabetes, 121(1), pp.27~31 (2013)
16. Kusaka I, "Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability?", Diabetes Obes Metab, 10(11), pp.1039~1046 (2008)[DOI]
17. Aubert G, "The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression", Metabolism, 60(3), pp.327~334 (2011)[DOI]
18. Malin SK, "Effects of metformin on weight loss: potential mechanisms", Curr Opin Endocrinol Diabetes Obes, 21(5), pp.323~329 (2014)[DOI]
19. Zheng W, "Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials", J Clin Psychopharmacol, 35(5), pp.499~509 (2015)[DOI]
20. "Assessing risk of bias in included studies;Cochrane handbook for systematic reviews of interventions. Version 5.1.0"[URL]
21. Xuan C, "No association between APOE <TEX>${\varepsilon}$<", TEX> 4 allele and multiple sclerosis susceptibility: a meta-analysis from 5472 cases and 4727 controls, 2011, pp.308(1-2), 110~116
22. 최윤영, "제 2형 당뇨 환자에서 자가혈당측정의 임상적 유용성 : 체계적문헌고찰 및 메타분석", 한국임상약학회지, 20(3), pp.183~192 (2010), 한국임상약학회
23. Baptista T, "Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial", Can J Psychiatry, 51(3), pp.192~196 (2006)[DOI]
24. Klein DJ, "A randomized, doubleblind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents", Am J Psychiatry, 163(12), pp.2072~2079 (2006)[DOI]
25. Baptista T, "Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial", Schizophr Res, 93(1-3), pp.99~108 (2007)[DOI]
26. Arman S, "A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents", Saudi Med J, 29(8), pp.1130~1134 (2008)
27. Wu RR, "Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study", Am J Psychiatry, 165(3), pp.352~358 (2008)[DOI]
28. Carrizo E, "Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study", Schizophr Res, 113(1), pp.19~26 (2009)[DOI]
29. Tao F, "Efficacy of metformin for treatment of olanzapine-induced weight gain in patients with first-episode schizophrenia", Xiandai Shiyong Yixue, 24, pp.58~59 (2012)
30. Wang M, "Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study", Schizophr Res, 138(1), pp.54~57 (2012)[DOI]
31. Chen CH, "Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study", J Clin Psychiatry, 74(5), pp.e424~e430 (2013)[DOI]
32. Jarskog LF, "Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder", Am J Psychiatry, 170(9), pp.1032~1040 (2013)[DOI]
33. de Silva VA, "Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study", J Psychopharmacol, 29(12), pp.1255~1261 (2015)[DOI]
34. Hebrani P, "Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder", J Res Med Sci, 20(4), pp.364~371 (2015)
35. Chiu CC, "Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study", PLoS One, 11(12), pp.e0168347~ (2016)[DOI]
36. Rado J, "A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population", J Clin Psychopharmacol, 36(2), pp.163~168 (2016)[DOI]
37. Wu RR, "Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebocontrolled trials", Mol Psychiatry, 21(11), pp.1537~1544 (2016)[DOI]
38. "Overweight & Obesity"[URL]
39. St Jeor ST, "A classification system to evaluate weight maintainers, gainers, and losers", J Am Diet Assoc, 97(5), pp.481~488 (1997)[DOI]
40. Anderson JW, "Obesity and disease management: effects of weight loss on comorbid conditions", Obes Res, 9(Suppl 4), pp.326S~334S (2001)[DOI]
41. Korean Academy of Medical Sciences, "Evidence-based Recommendations for Hypertension in Primary Care 2014"
42. Brown JD, "Effects on cardiovascular risk factors of weight losses limited to 5-10", Transl Behav Med, 6(3), pp.339~346 (2016)[DOI]

관련 논문AI추천